Kang HN - Search Results

1

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.

Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC. Yun MR, et al. Among authors: kang hn. EMBO Mol Med. 2019 Dec;11(12):e10581. doi: 10.15252/emmm.201910581. Epub 2019 Oct 21. EMBO Mol Med. 2019. PMID: 31633304 Free PMC article.

2

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.

Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, Paik S, Kim DJ, Kim JH, Cho BC. Kang CW, et al. Among authors: kang hn. Mol Cancer Ther. 2015 Oct;14(10):2238-48. doi: 10.1158/1535-7163.MCT-15-0350. Epub 2015 Jul 24. Mol Cancer Ther. 2015. PMID: 26208525

3

Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.

Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC. Pyo KH, et al. Among authors: kang hn. J Thorac Oncol. 2017 Mar;12(3):491-500. doi: 10.1016/j.jtho.2016.10.022. Epub 2016 Nov 9. J Thorac Oncol. 2017. PMID: 27836576 Free article.

4

Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.

Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, Kim HR. Kang HN, et al. Lung Cancer. 2018 Oct;124:168-178. doi: 10.1016/j.lungcan.2018.08.008. Epub 2018 Aug 11. Lung Cancer. 2018. PMID: 30268457

5

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.

Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC. Yun J, et al. Among authors: kang hn. Clin Cancer Res. 2019 Apr 15;25(8):2575-2587. doi: 10.1158/1078-0432.CCR-18-2906. Epub 2019 Jan 22. Clin Cancer Res. 2019. PMID: 30670498

6

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.

Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC. Yun MR, et al. Among authors: kang hn, kang sg. Clin Cancer Res. 2020 Jul 1;26(13):3287-3295. doi: 10.1158/1078-0432.CCR-19-2777. Epub 2020 Apr 8. Clin Cancer Res. 2020. PMID: 32269053 Free PMC article.

7

ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

Kang HN, Kim SH, Yun MR, Kim HR, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC. Kang HN, et al. Lung Cancer. 2016 May;95:57-64. doi: 10.1016/j.lungcan.2016.02.013. Epub 2016 Feb 27. Lung Cancer. 2016. PMID: 27040853

8

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Kim SM, Kim H, Jang KW, Kim MH, Sohn J, Yun MR, Kang HN, Kang CW, Kim HR, Lim SM, Moon YW, Kim JH, Paik S, Cho BC. Kim SM, et al. Among authors: kang hn, kang cw. Mol Cancer Ther. 2016 Jul;15(7):1627-36. doi: 10.1158/1535-7163.MCT-15-0375. Epub 2016 May 11. Mol Cancer Ther. 2016. Retraction in: Mol Cancer Ther. 2017 Oct;16(10):2326. doi: 10.1158/1535-7163.MCT-17-0547 PMID: 27196768 Retracted.

9

Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.

Kim YJ, Baek DS, Lee S, Park D, Kang HN, Cho BC, Kim YS. Kim YJ, et al. Among authors: kang hn. Cancer Lett. 2019 Dec 1;466:23-34. doi: 10.1016/j.canlet.2019.09.005. Epub 2019 Sep 12. Cancer Lett. 2019. PMID: 31521695

10

Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.

Kang HN, Kim JH, Park AY, Choi JW, Lim SM, Kim J, Shin EJ, Hong MH, Pyo KH, Yun MR, Kim DH, Lee H, Yoon SO, Kim DH, Park YM, Byeon HK, Jung I, Paik S, Koh YW, Cho BC, Kim HR. Kang HN, et al. BMC Cancer. 2020 Apr 15;20(1):316. doi: 10.1186/s12885-020-06786-5. BMC Cancer. 2020. PMID: 32293356 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters